ABSTRACT
The granuloma is a complex structure, contributing to the overall spectrum of tuberculosis (TB). We characterised 44 fresh human pulmonary TB lesion samples from 13 patients (drug-sensitive and multi-drug resistant TB) undergoing therapeutic surgery using RNA-Sequencing. We confirmed a clear separation between the granuloma and adjacent non-lesional tissue, with the granuloma samples consistently displaying increased inflammatory profile despite heterogeneity. Using weighted correlation network analysis, we identified 17 transcriptional modules associated with granulomata and demonstrated a gradient of immune-related transcript abundance according to the granuloma’s spatial organization. Furthermore, we associated the modular transcriptional signature of the TB granuloma with clinical surrogates of treatment efficacy and TB severity. We show that in patients with severe disease, the IFN/cytokine signalling and neutrophil degranulation modules were overabundant, while tissue organization and metabolism modules were under-represented. Our findings provide evidence of a relationship between clinical parameters, treatment response and immune signatures at the infection site.
Competing Interest Statement
The authors declare the following competing interests: C.V salary is covered by ISCIII (CPII18/00031) and Fundació Institut dInvestigació en Ciencies de la Salut Germans Trias I Pujol (IGTP). C.V is an unpaid board member of the following non-profit organizations: the FUITB foundation and the ACTMON foundation. Neither the ISCIII, the IGTP, the FUITB nor ACTMON have had any role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT02715271
Funding Statement
This work was supported by: 1) the Plan Nacional I + D + I co-financed by ISCIII-Subdireccion General de Evaluacion and Fondo-EU de Desarrollo Regional (FEDER) through PI16/01511, PI20/01424, CP13/00174, CPII18/00031 and CB06/06/0031. 2) The European Union’s Horizon 2020 research and innovation program under grant agreement No 847762. 3) The Catalan Agency for Management of University and Research Grants (AGAUR) through 2017SGR500, 2021 SGR 00920 and 2017 FI_B_00797. 4) The Spanish Society of Pneumology and Thoracic Surgery (SEPAR) (16/023). 5) The Wellcome Trust, the Medical Research Foundation grants (206508/Z/17/Z and MRF-160-0008-ELP-KAFO-C0801) and the NIHR Imperial College BRC to M.K. 6) Wellcome Trust (204538/Z/16/Z) and National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (NC/R001669/1) grants to S.J.W. 7) Á.D.R.-Á and J.C-R were supported by AGAUR grant 2022_FI_B00528 and 2019 FI_B01024, respectively. 8) CA received funding from CIBERehd (CB06/04/0033) and AGAUR (2017-SGR-490 and 2021 SGR-01186) and was supported by Ramon y Cajal grant of the Ministry of Science and Innovation of Spain (RYC-2010-07249). 9) AOG is supported by The Francis Crick Institute which receives its core funding from Cancer Research UK (FC001126), the UK Medical Research Council (FC001126), and the Wellcome Trust (FC001126); before that by the UK Medical Research Council (MRC U117565642).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committees/IRBs of the National Center for Tuberculosis and Lung Disease (IRB00007705 NCTLD Georgia #1, IORG0006411) and the Germans Trias i Pujol Hospital (EC: PI-16-171 and CEI PI-17-064) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵& Sergo Vashakidze and Cristina Vilaplana should be considered last co-authors
The previous version of our manuscript fell short in conveying the full richness of the RNA-sequencing dataset from granulomas in a rare cohort of TB patients. To address this, we conducted a comprehensive reanalysis of the bioinformatics data. This effort led to significant changes in the manuscript’s structure, impacting key findings, methodology, figures, narrative flow and authorship. Our approach involved employing an unbiased modular method to deepen our analysis and clarify the data. This allowed us to successfully correlate our findings with clinical indicators of TB disease severity and treatment response. Overall, these revisions have strengthened the scientific robustness and relevance of our paper.
DATA AVAILABILITY
Patient’s data were transferred to a data frame (SH-TBL Cohort metadata) and are freely accessible (doi: 10.17632/knhvdbjv3r.1). All metadata and sequencing data from this manuscript have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database and will be released after manuscript acceptance in a peer-reviewed scientific journal.
